You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

TAMIFLU Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Tamiflu patents expire, and when can generic versions of Tamiflu launch?

Tamiflu is a drug marketed by Roche and is included in two NDAs.

The generic ingredient in TAMIFLU is oseltamivir phosphate. There are eight drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the oseltamivir phosphate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tamiflu

A generic version of TAMIFLU was approved as oseltamivir phosphate by NATCO on August 3rd, 2016.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TAMIFLU?
  • What are the global sales for TAMIFLU?
  • What is Average Wholesale Price for TAMIFLU?
Drug patent expirations by year for TAMIFLU
Drug Prices for TAMIFLU

See drug prices for TAMIFLU

Drug Sales Revenue Trends for TAMIFLU

See drug sales revenues for TAMIFLU

Recent Clinical Trials for TAMIFLU

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Children's Hospital of PhiladelphiaPhase 4
Genentech, Inc.Phase 4
Weill Medical College of Cornell UniversityPhase 4

See all TAMIFLU clinical trials

Pharmacology for TAMIFLU
Drug ClassNeuraminidase Inhibitor
Mechanism of ActionNeuraminidase Inhibitors
Paragraph IV (Patent) Challenges for TAMIFLU
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TAMIFLU for Oral Suspension oseltamivir phosphate 6 mg/mL 021246 1 2015-06-18
TAMIFLU Capsules oseltamivir phosphate 30 mg and 45 mg 021087 1 2011-08-02
TAMIFLU Capsules oseltamivir phosphate 75 mg 021087 1 2010-11-15

US Patents and Regulatory Information for TAMIFLU

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Roche TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087-003 Jul 2, 2007 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Roche TAMIFLU oseltamivir phosphate FOR SUSPENSION;ORAL 021246-002 Mar 21, 2011 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Roche TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087-002 Jul 2, 2007 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Roche TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087-001 Oct 27, 1999 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Roche TAMIFLU oseltamivir phosphate FOR SUSPENSION;ORAL 021246-001 Dec 14, 2000 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TAMIFLU

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Roche TAMIFLU oseltamivir phosphate FOR SUSPENSION;ORAL 021246-001 Dec 14, 2000 ⤷  Sign Up ⤷  Sign Up
Roche TAMIFLU oseltamivir phosphate FOR SUSPENSION;ORAL 021246-002 Mar 21, 2011 ⤷  Sign Up ⤷  Sign Up
Roche TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087-003 Jul 2, 2007 ⤷  Sign Up ⤷  Sign Up
Roche TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087-002 Jul 2, 2007 ⤷  Sign Up ⤷  Sign Up
Roche TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087-002 Jul 2, 2007 ⤷  Sign Up ⤷  Sign Up
Roche TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087-001 Oct 27, 1999 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for TAMIFLU

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0759917 0290024-9 Sweden ⤷  Sign Up
0759917 CA 2002 00027 Denmark ⤷  Sign Up
0759917 90991 Luxembourg ⤷  Sign Up
0759917 SPC031/2002 Ireland ⤷  Sign Up SPC031/2002: 20021107, EXPIRES: 20160226
0759917 38/2002 Austria ⤷  Sign Up PRODUCT NAME: OSELTAMIVIR PHOSPHAT; REGISTRATION NO/DATE: EU/1/02/222/001 EU/1/02/222/002 20020620
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.